Publicaciones en las que colabora con Francisco Suárez López (7)

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  2. Influence of donor liver CYP3A4∗20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

    Pharmacogenetics and Genomics, Vol. 28, Núm. 2, pp. 41-48

2016

  1. Erratum: Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study (Journal of Hepatology (2015) 62 (92-100))

    Journal of Hepatology

  2. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study

    Journal of Hepatology, Vol. 62, Núm. 1, pp. 92-100

2013

  1. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in caucasian spanish liver transplant patients

    Journal of Clinical Pharmacology, Vol. 53, Núm. 11, pp. 1146-1154

2011

  1. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large multicenter cohort study

    Transplantation, Vol. 92, Núm. 3, pp. 334-340